During postmarketing surveillance which includes other dosage forms and other patient populations, the following adverse events ended up reported. The development of diagnostic criteria has enabled greater recognition of menstrual migraine being a highly prevalent and disabling condition meriting unique treatment. Whilst several therapeutic trials